Showing 7891-7900 of 9757 results for "".
- FDA Issues Warning to Matte Beauty Over Unapproved Chemical Peelshttps://practicaldermatology.com/news/fda-issues-warning-matte-beauty-over-unapproved-chemical-peels/2467661/The U.S. Food and Drug Administration (FDA) recently sent a warning letter to Matte Beauty, addressing what the agency described as significant regulatory violations regarding their chemical peel products. According to the July 25 letter, the products in question include “TCA 100% Skin Pe
- Cemiplimab Shows Promising Results in Refractory cSCC Patientshttps://practicaldermatology.com/news/cemiplimab-shows-promising-results-refractory-cscc-patients/2467554/New research suggests cemiplimab is safe and effective in patients with refractory locally advanced (LA) and metastatic cutaneous squamous cell carcinoma (cSCC). Researchers for the retrospective single-center Canadian study sought to characterize the real-world use of cemiplimab in pati
- Delgocitinib Clinical Trials Data Publishedhttps://practicaldermatology.com/news/delgocitinib-clinical-trials-data-published/2467444/LEO Pharma A/S announced that the findings of the DELTA 1 and DELTA 2 phase 3 clinical trials for delgocitinib cream have been published in the peer-reviewed periodical The Lancet. This is the first time The Lancet has published data on an investigational topical pan-Janus kinase (JAK) inhibitor
- Inaugural ElderDerm Conference Hosted by GWhttps://practicaldermatology.com/news/inaugural-elderderm-conference-hosted-gw/2467204/The inaugural ElderDerm Conference was held June 6 in Washington, DC, hosted by the GW Department of Dermatology. Co-Director Adam Friedman, MD, a Practical DermatologyÒ Editorial Board member, presented two talks: “Hair Loss in the Elderly: Considerations and Therapeutic Approaches” and
- Event Promotes Anti-Itch Cream for Stopping Pesky Bugs From Disrupting Summer Funhttps://practicaldermatology.com/news/event-promotes-anti-itch-cream-stopping-pesky-bugs-disrupting-summer-fun/2467168/Summer is in full swing and as patients spend more time outdoors, bug bites and other skin irritants will find a way to disrupt the fun.
- Study: Oral Minoxidil Not Superior to Topical Minoxidilhttps://practicaldermatology.com/news/non-oral-and-topical-minoxidil/2467152/Daily oral minoxidil, 5 mg was not superior to topical minoxidil, 5%, in a population of male patients with alopecia according to a new study in JAMA Dermatology. "There has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment," the autho
- Vyne Therapeutics Doses First Patient in Phase 2b Vitiligo Trial of Novel BET Inhibitorhttps://practicaldermatology.com/news/vyne-therapeutics-doses-first-patient-phase-2b-vitiligo-trial-novel-bet-inhibitor/2467132/Vyne Therapeutics announced that the first subject has been dosed in a phase 2b trial evaluating VYN201 in subjects with either active or stable nonsegmental vitiligo. VYN201 is a novel pan-bromodomain and extra-terminal domain (BET) inhibitor designed for local administration. Topline data from
- Study IDs New Potential Targets for Rare Complication of Melanomahttps://practicaldermatology.com/news/study-ids-new-potential-targets-rare-complication-melanoma/2467090/New research from the Moffitt Cancer Center may have uncovered new therapeutic targets for leptomeningeal metastasis (LMD) in melanoma, a severe complication affecting 5%-8% of melanoma patients.
- Study: Upadacitinib Produces Sustained Improvements in 140 Weekshttps://practicaldermatology.com/news/study-upadacitinib-produces-sustained-improvements-140-weeks/2467045/Patients with moderate-to-severe atopic dermatitis (AD) experienced sustained improvements in skin signs/symptoms through 140 weeks while receiving upadacitinib and rates of long-term patient-related outcome improvements were numerically higher with upadacitinib 30 mg compared with upadacitinib 1
- More Positive Upadacitinib Data Presentedhttps://practicaldermatology.com/news/more-positive-upadacitinib-data-presented/2467018/New data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from June 8-10 in Chicago, Illinois, built on previously published top-line results comparing upadacitinib to dupilumab by demonstrating superiority for all ranked secondary endpoints at varying response levels and time